Detail akcie Ocular Therapeutix online

Business Summary: Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Its earlier stage development assets include: axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy; travoprost intracameral implant (OTX-TIC), is under Phase II clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and dexamethasone intracanalicular insert (OTX-DED), for the short-term treatment of the signs and symptoms of dry eye disease; and cyclosporine intracanalicular insert (OTX-CSI), for the chronic treatment of dry eye disease, both of which have completed Phase II clinical trials.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Ocular Therapeutix Inc revenues increased 17% to $43.6M. Net loss decreased 7% to $51.5M. Revenues reflect Product revenue, net increase of 18% to $43.2M. Lower net loss reflects Interest Income increase from $376K to $2.5M (income), Stock-based Compensation in SGA decrease of 16% to $2.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.72 to -$0.66.